Hypersensitivity and Anaphylactoid Reactions to Ciprofloxacin

1992 ◽  
Vol 26 (9) ◽  
pp. 1081-1084 ◽  
Author(s):  
Robert L. Deamer ◽  
John G. Prichard ◽  
Geoffrey J. Loman
Keyword(s):  
Infected Patient ◽  
Anaphylactoid Reaction ◽  
Hypersensitivity Reactions ◽  
Surveillance Studies ◽  
Infected People ◽  
Case Summary ◽  
Life Threatening ◽  
Anaphylactoid Reactions ◽  
Oral Ciprofloxacin ◽  
Special Risk

OBJECTIVE: To report three cases of life-threatening hypersensitivity reactions to the oral administration of ciprofloxacin. CASE SUMMARY: Life-threatening hypersensitivity reactions to oral ciprofloxacin, characterized by diffuse, erythematous, nonpruritic, blanching rash, with fever and hypotension, occurred in two HIV-infected patients. One of these reactions was considered anaphylactoid. A similar hypersensitivity reaction was documented in a non—HIV-infected patient. DISCUSSION: Premarketing clinical trials described no reports of life-threatening anaphylactoid hypersensitivity reactions to ciprofloxacin. However, postmarketing surveillance studies have documented their occurrence. Seven cases of anaphylactoid reaction to ciprofloxacin have now been documented in HIV-infected patients. CONCLUSIONS: As with trimethoprim/sulfamethoxazole, HIV-infected people treated with ciprofloxacin may be at special risk for hypersensitivity reactions.

Hypersensitivity Anaphylactoid Reaction to Pefloxacin in a Patient with Aids

1996 ◽  
Vol 30 (6) ◽  
pp. 612-614 ◽  
Author(s):  
Mogbil A Al-Hedaithy ◽  
Ayman M Noreddin ◽  
Rafaela Mena ◽  
Mare-Claude Vanier
Keyword(s):  
Broad Spectrum ◽  
Mycobacterium Avium Complex ◽  
Anaphylactoid Reaction ◽  
Antimicrobial Agents ◽  
New Drugs ◽  
Pertinent Literature ◽  
Case Summary ◽  
Severe Hypotension ◽  
Life Threatening ◽  
Anaphylactoid Reactions

Objective To report a life-threatening anaphylactoid reaction to oral pefloxacin in a patient with AIDS and to review the pertinent literature. Case Summary A 32-year-old woman with AIDS developed an anaphylactoid reaction following a second exposure to oral pefloxacin. This reaction was characterized by severe hypotension, dizziness, itching, and fever. Discussion Fluoroquinolones are broad-spectrum antimicrobial agents. They are used frequently in patients with AIDS for numerous indications, including treatment of Mycobacterium avium complex. Pefloxacin, a broad-spectrum fluoroquinolone, was introduced in France in 1985. Since then, many patients with AIDS have been treated with this drug. Several cases of anaphylactoid reactions to ciprofloxacin have been documented in patients with HIV infection. To our knowledge, this is the first reported case of an anaphylactoid reaction to pefloxacin in a patient with AIDS. Conclusions There is a need for continued vigilance in the reporting of adverse drug reactions in patients with AIDS, especially with new drugs. Also, care must be taken in introducing drugs, including fluoroquinolones, to this patient population.

Successful Desensitization to Oxaliplatin

2005 ◽  
Vol 39 (5) ◽  
pp. 966-969 ◽  
Author(s):  
Lydia ◽  
Nishan H Fernando ◽  
Hurbert I Hurwitz ◽  
Michael A Morse
Keyword(s):  
White Woman ◽  
Initial Response ◽  
Response To Therapy ◽  
Controlled Environment ◽  
Metastatic Colon Cancer ◽  
Hypersensitivity Reactions ◽  
Platinum Compounds ◽  
Probability Scale ◽  
Case Summary ◽  
Life Threatening

OBJECTIVE: To report the successful desensitization of a patient to oxaliplatin utilizing an 8-hour desensitization regimen in a controlled environment. CASE SUMMARY: A 53-year-old white woman with metastatic colon cancer was receiving oxaliplatin, bevacizumab, and capecitabine every 2 weeks, with a partial response to therapy. On her fifth cycle of this regimen, she experienced diaphoresis, hypotension, nausea, abdominal cramping, and coryza. According to the Naranjo probability scale, oxaliplatin, and not bevacizumab, was the probable cause of the hypersensitivity reaction. The woman continued therapy with capecitabine and bevacizumab, resulting in stable disease. Due to her initial response to the oxaliplatin-based regimen, it was decided to attempt desensitization to oxaliplatin in a controlled, inpatient environment. An 8-hour desensitization schedule was employed, and the patient successfully completed an additional 3 cycles with full-dose oxaliplatin. DISCUSSION: Hypersensitivity reactions to platinum-containing compounds are well described and potentially life threatening. With expanded use of oxaliplatin in various malignancies, an increased number of hypersensitivity reactions will likely be reported. Patients with previous hypersensitivity reactions to carboplatin are at risk for similar reactions to oxaliplatin. We achieved successful desensitization for oxaliplatin using increased concentrations of the drug over an 8-hour period concomitant with oral and intravenous corticosteroids and histamine blockers. CONCLUSIONS: Hypersensitivity reactions to platinum compounds may result in discontinuation of active therapies in patients with metastatic disease. Desensitization to oxaliplatin is possible utilizing this approach.

Anaphylactoid Reaction to Ciprofloxacin

2003 ◽  
Vol 37 (7-8) ◽  
pp. 1018-1023 ◽  
Author(s):  
Dora Y Ho ◽  
Jessica C Song ◽  
Clifford C Wang
Keyword(s):  
Adverse Effects ◽  
Anaphylactoid Reaction ◽  
Complete Recovery ◽  
Hiv Positive ◽  
Severe Hypotension ◽  
Life Threatening ◽  
Anaphylactoid Reactions ◽  
Challenge Tests ◽  
First Time ◽  
Hiv Negative

OBJECTIVE: To report a case of anaphylactoid reaction in an HIV-negative patient associated with the administration of intravenous ciprofloxacin. CASE SUMMARY: A 79-year-old Armenian man developed an anaphylactoid reaction following a first-time exposure to intravenous ciprofloxacin. This reaction was characterized by severe hypotension, wheezing, tachypnea, tachycardia, and pruritus. The patient had complete recovery once ciprofloxacin treatment was terminated and supportive care was provided. DISCUSSION: Fluoroquinolones are important therapeutic agents in the management of infectious diseases and are generally safe and well tolerated. Anaphylactoid and anaphylactic reactions have been documented as adverse effects of ciprofloxacin, ofloxacin, norfloxacin, levofloxacin, and moxifloxacin. To date, >33 cases have been reported with ciprofloxacin, of which at least 10 occurred in HIV-positive patients. In Europe, 15 cases of anaphylactoid reactions to ofloxacin have been reported and, more recently, with moxifloxacin. Since anaphylactoid reactions are potentially life threatening, the administration of fluoroquinolones to patients who have experienced a prior reaction to any of these agents should be avoided, unless tolerance has been confirmed by oral challenge tests. CONCLUSIONS: The anaphylactoid reaction in our patient was probably induced by ciprofloxacin as validated by the Naranjo probability scale. Although anaphylactoid/anaphylactic reactions are rare adverse effects of ciprofloxacin and other fluoroquinolones, clinicians should be aware of this potentially fatal event.

Anaphylactoid Reactions Associated with Ondansetron

1994 ◽  
Vol 28 (9) ◽  
pp. 1029-1030 ◽  
Author(s):  
Joyce L. Kossey ◽  
Karl K. Kwok
Keyword(s):  
Adverse Effects ◽  
Medical Records ◽  
Anaphylactoid Reaction ◽  
Journal Articles ◽  
Medline Search ◽  
Case Summary ◽  
Anaphylactoid Reactions ◽  
The Individual ◽  
The Right ◽  
Conclusive Data

OBJECTIVE: To describe two patients with anaphylactoid-type reactions to ondansetron. CASE SUMMARY: A 41-year-old man with grade III leiomyosarcoma of the right tibia was admitted to the hospital for his second dose of first-cycle neoadjuvant intraarterial cisplatin 60 mg/m2 therapy. He experienced an anaphylactoid reaction following intravenous ondansetron infusion that was confirmed on rechallenge. In a second case, premedication with intravenous ondansetron resulted in an anaphylactoid reaction in a 44-year-old woman with stage III ovarian cancer receiving her ninth course of cyclophosphamide and carboplatin. Both patients had received ondansetron previously with no adverse effects. DISCUSSION: Peer-reviewed journal articles and reports, obtained through a MEDLINE search, were reviewed. Information on the individual cases was obtained from the patients' medical records. Preservative changes in ondansetron infusion were examined as possible causes of the anaphylactoid reactions in our patients, but no conclusive data linking them were found. CONCLUSIONS: The efficacy and safety of ondansetron has led to the widespread use of this medication in the treatment of nausea and vomiting caused by cancer chemotherapy and radiation therapy. Practitioners should be made aware that acute severe anaphylactoid reactions could occur in patients who have previously received ondansetron with no adverse effects.

scholarly journals Intravenous ondansetron induced hypersensitivity reaction: a case report

2021 ◽  
Vol 10 (5) ◽  
pp. 578
Author(s):  
S. Nitya ◽  
M. Shanthi ◽  
R. Meenakshi ◽  
S. Kiruthika
Keyword(s):  
Case Report ◽  
Hypersensitivity Reaction ◽  
Receptor Antagonist ◽  
Rare Case ◽  
Anaphylactoid Reaction ◽  
Rational Approach ◽  
Health Practitioners ◽  
Rare Case Report ◽  
Life Threatening ◽  
Anaphylactoid Reactions

Ondansetron a selective 5-HT3 receptor antagonist has been widely used as a prophylactic antiemetic for chemotherapy induced and anaesthesia related nausea and vomiting. Anaphylaxis and anaphylactoid reaction rarely occur in less than 1% of the patients and may lead to potentially life-threatening events. This study is one such rare case report of hypersensitivity reaction to intravenous ondansetron in a perioperative setting. Familiarity about anaphylactoid reactions to intravenous ondansetron among the health practitioners would help them to bring about a rational approach to decrease its incidence.

scholarly journals Acute pulmonary embolism in COVID-19 patient: a case report of free-floating right heart thrombus successfully treated with fibrinolysis

2020 ◽  
Author(s):  
Fernando Scudiero ◽  
Antonino Pitì ◽  
Roberto Keim ◽  
Guido Parodi
Keyword(s):  
Pulmonary Embolism ◽  
High Risk ◽  
Retrospective Studies ◽  
Right Heart ◽  
Clinical Issue ◽  
Systemic Thrombolysis ◽  
Case Summary ◽  
High Prevalence ◽  
Life Threatening ◽  
Complex Scenario

Abstract Background Despite the fast-growing understanding of the coronavirus disease 2019 (COVID-19), patient management remains largely empirical or based on retrospective studies. In this complex scenario, an important clinical issue appears to be represented by the high prevalence of thromboembolic events, but the data regarding high-risk pulmonary embolism (PE) is still not available. Case summary A patient with COVID-19 developed sudden shortness of breath and hypoxia. Early echocardiographic diagnosis of high-risk PE related to right heart thrombus was performed. Systemic thrombolysis was administered with excellent clinical and haemodynamic response. Discussion Pulmonary thromboembolism is a common occurrence in severe COVID-19 infection. In our experience, systemic thrombolysis proved to be effective and for this reason may be considered for life-threatening PE in COVID-19 patients.

scholarly journals Acute upper airway obstruction as a life-threatening complication of ventral bulla osteotomy: report of two consecutive cases

2021 ◽  
Vol 7 (1) ◽  
pp. 205511692110059
Author(s):  
Michal Vlasin ◽  
Richard Artingstall ◽  
Barbora Mala
Keyword(s):  
Airway Obstruction ◽  
Clinical Signs ◽  
Upper Airway ◽  
Upper Airway Obstruction ◽  
Single Session ◽  
Inflammatory Polyp ◽  
Case Summary ◽  
First Case ◽  
Life Threatening

Case summary This paper presents two cases of acute postoperative upper airway obstruction following ventral bulla osteotomy (VBO) in cats. The first cat underwent a unilateral left-sided VBO for a suspected inflammatory polyp. The second cat underwent a single-session bilateral VBO procedure for bilateral otitis media. In the first case, immediate re-intubation and a gradual lightening of the anaesthetic plane resolved the clinical signs; in the second case, the patient deteriorated and went into acute cardiorespiratory arrest and received cardiopulmonary resuscitation. Both patients recovered well and were discharged home 3 days after surgery. Both cases were reported to show no further clinical signs on postoperative follow-up 3 weeks and 4 months after surgery, respectively. Relevance and novel information Upper airway obstruction should be regarded as a potential complication of VBO in cats.

The Challenges of Biomedical Waste Management During the Ongoing Coronavirus Disease-19 (COVID-19) Pandemic: The Current Scenario

2021 ◽  
Vol 13 ◽  
Author(s):  
Sabitha Vadakedath ◽  
Venkataramana Kandi ◽  
Tarun Kumar Suvvari ◽  
L V Simhachalam Kutikuppala ◽  
Vikram Godishala ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Complex Nature ◽  
The Novel ◽  
Waste Collection ◽  
Biomedical Waste ◽  
Infected People ◽  
Life Threatening ◽  
Current Scenario ◽  
Constant Observation ◽  
Novel Coronavirus

: The novel Coronavirus (SARS-CoV-2) that has emerged and spread throughout the world causing CoV disease-19 (COVID-19) has since its discovery affected not only humans and animals but also the environment. Because of the highly infectious nature of the virus, and the respiratory aerosol transmission route, face masks and personal protective equipment have become mandatory for public and healthcare workers, respectively. Also, the complex nature of the pathogenicity of the virus, wherein, it has been associated with mild, moderate, and severe life-threatening infections, has warranted increased laboratory testing and placing the infected people in isolation and under constant observation in quarantine centers or at dedicated hospitals. Some infected people, who are generally healthy, and do not show symptoms have been placed in home quarantines. At this juncture, there has been increased amount of biomedical waste (BMW), and infectious general waste along with plastic disposable recyclable and non-recyclable waste. The increased BMW along with the potentially hazardous plastic waste collection, segregation, transport, and disposal has assumed increased significance during the ongoing pandemic. Therefore, this review attempts to investigate the current scenario of BMW management and strategies to minimize BMW and prevent potential environmental pollution.

Tobramycin-Induced Hypersensitivity Reaction

1995 ◽  
Vol 29 (7-8) ◽  
pp. 704-706 ◽  
Author(s):  
Janet S Schretlen-Doherty ◽  
William G Troutman
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Hypersensitivity Reaction ◽  
Aminoglycoside Antibiotic ◽  
Drug Regimen ◽  
Hypersensitivity Reactions ◽  
Left Chest ◽  
The Third ◽  
Access System ◽  
Case Summary

Objective: To report a case of a hypersensitivity reaction associated with the use of intravenous tobramycin in a patient with cystic fibrosis. Case Summary: An 18-year-old man was hospitalized for exacerbation of his cystic fibrosis. Tobramycin 125 mg iv q6h and ceftazidime 2 g iv q8h were administered through the patient's implantable access system in the left chest. Within seconds of receiving the third dose of tobramycin, the patient experienced shaking, his left arm turned white, and urticaria and pruritus were noted on the left side of the patient's chest. The patient had experienced a similar incident, accompanied by breathing difficulty, with intravenous tobramycin 4 years príor to this incident. The patient had been skin-tested for tobramycin allergy and had been desensitized and was receiving tobramycin since that time without incident. The patient's desensitization was maintained with tobramycin 160 mg/d hs by nebulization, but the drug had been discontinued by the patient 6 months prior to the latest event. Discussion: Hypersensitivity reactions to aminoglycosides are unusual. Hypersensitivity to 1 aminoglycoside antibiotic frequently is associated with hypersensitivity to at least 1 other aminoglycoside. In patients who develop hypersensitivity to an aminoglycoside antibiotic, desensitization may be an effective alternative to changing therapy. Conclusions: Tobramycin is very important in the drug regimen for Pseudomonas aeruginosa infections in patients with cystic fibrosis. Effective desensitization can be maintained by daily administration of nebulized tobramycin.

Sign in / Sign up

Export Citation Format

Share Document